Last reply 1 week ago
Do you take Alemtuzumab?

Not something to worry about, just something to be aware of. It is the last 2 or 3 sentences of the abstract (below) to internalise and raise with your Neuro.

https://www.frontiersin.org/articles/10.3389/fimmu.2020.00124/abstract

>>
At the population level this enables the drug to work in most pwMS, but in some individuals level, as we show here, antibody neutralization appears to be sufficiently severe to reduce efficacy and allow disease-breakthrough. It is therefore imperative that efficacy of lymphocyte depletion and the anti-drug response is monitored in people requiring additional cycles of treatment, notably following disease breakthrough. This may help inform whether to re-treat or switch to another disease modifying treatment.
<<

Add categories

Browse categories and add by clicking on them

You can remove current categories below by clicking the ‘x’.


laurab90
1 week ago

After asking for a simpler explanation of the article , I’ll post the reply from @dominics
My brain couldn’t quite process the info 🙈😂………thanks Dom , much appreciated 😊

No worries and nothing to be worried about. Many drugs are a challenge to the body and so it responds by trying to stop that. The way it does it is to create neutralising antibodies (flash way of saying ass-kicker bodyguards for the body).

In some – some – people with Alemtuzumab they produce so many of these antibodies that it may – may – affect how well the drug works.

It is a heads up to neuros that if a patient on Alemtuzumab has breakthrough (new) disease activity after a few rounds of treatment then it is worth testing for and possibly switching to – say – ocrelizumab or the soon to be approved ofamtumumab.

Not to fret. If the Alemtuzumab is not kicking MS’s arse after a few goes then this is likely the reason why.


itsmewithms
1 week ago

This one is a bit different but Dr Boster Explains in language I can understand 😉

Join Shift.ms to reply to this post.

Become part of the community so you can chat, compare and learn from other MSers.